AcouSort AB

Equities

ACOU

SE0009189608

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 03:23:49 2024-05-22 am EDT			5-day change	1st Jan Change
10.25 ^SEK	-1.44%		+4.59%	-34.08%

May. 02	AcouSort AB to Present Two Posters Highlighting the Value of Acoustofluidics Sample Preparation	CI
Apr. 29	AcouSort AB and GenSensor SAS Enters Collaboration Aiming At Improving Bioreactor Culturing	CI

AcouSort Announces Board Changes

October 12, 2021 at 02:30 am EDT

AcouSort announced that CEO Martin Linde is on sick leave. Martin Linde has also chosen to leave the board of AcouSort to focus on his recovery. The Board will shortly convene an Extraordinary General Meeting to elect a new Board member to replace Martin.

Latest news about AcouSort AB

AcouSort AB to Present Two Posters Highlighting the Value of Acoustofluidics Sample Preparation	May. 02	CI
AcouSort AB and GenSensor SAS Enters Collaboration Aiming At Improving Bioreactor Culturing	Apr. 29	CI
AcouSort Initiates Two AcouWash Lease Collaborations with Potential OEM Partners	Apr. 26	CI
AcouSort AB Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
AcouSort Raises Nearly SEK25 Million from Rights Offering	Dec. 05	MT
AcouSort Seeks Nearly SEK25 Million from Rights Offering; Stock Falls	Nov. 07	MT
AcouSort AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
AcouSort Delivers Fully Functional Test System for Automated Cell Handling Within Cell Therapy	23-10-16	CI
AcouSort AB Delivers and Installed an AcouWash System At the Faculty of Medicine At the University of Porto, Portugal	23-09-19	CI
AcouSort AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
AcouSort's Cell Therapy Partnership Enters Evaluation Phase	23-07-05	MT
AcouSort AB Announces Cell Therapy Collaboration with Leading Global Life Science Company Continues to Expand	23-07-05	CI
AcouSort AB Recruits Henrik Johansson to the Position as Director of Research and Technology	23-06-16	CI
AcouSort AB Delivers Unique Acouwash 2 System to Lund University	23-06-07	CI
AcouSort AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
AcouSort AB Launches Next Generation AcouTrap at CYTO 2023	23-05-22	CI
AcouSort AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
Medtech Group AcouSort Extends Collaboration on Cell Therapies	23-01-20	MT
AcouSort, BlueCell Near Stem Cell Therapy Project Completion	23-01-19	MT
AcouSort AB and the Biowings Project Creates New Opportunities for Large-Scale Production and Exosome-Based Diagnostics	22-12-01	CI
AcouSort AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
AcouSort Enters Cell Therapy Partnership with Global Life Science Company	22-11-14	MT
AcouSort Expands Its Cell Therapy Efforts and Enters Collaboration with Global Life Science Company	22-11-14	CI
AcouSort to Supply Lund University with Unique Pre-Focusing Technology to Enable High Precision Cell Separation	22-11-11	CI
Acousort Signs Exclusive Distribution Agreement with Its Physio-Tech	22-10-21	CI

Chart AcouSort AB

Duration

Period

More charts

Company Profile

Acousort AB is a Sweden-based company engaged in the medical technology. The Company develops, produces and sells standalone laboratory products and integrated original equipment manufacturer (OEM) solutions where ultrasound is used to separate, wash and enrich cells, exosomes and other biological particles for research and diagnostics. Its product portfolio includes AcouWash and AcouTrap that are targeting separation, washing and enrichment applications within cell, bacteria and extracellular vesicle research. In addition, the Company develops proprietary bioanalytical and clinical applications based on acoustophoresis, and offers custom-developed acoustophoresis applications.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACOUSORT AB	-34.08%	14.51M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+44.19%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research